R.PR
REGISTERED-PRINCIPAL REGISTER
05/03/2022
Back to search
Official data from USPTO
CLODEW
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
8
Latest update
05/03/2022
Trademark type
Word
Nice classes
5
Filing date
05/07/2021
Registration date
05/03/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/03/2022
Last transaction
05/03/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
03
Owner location
Gyeonggi-do, KR
Examiner
HOWARD, PARKER WALDRIP
Law office
N90
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
DAEWOONG PHARMACEUTICAL CO., LTD.
Representatives
JOHN M. KIM IPLA, LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Botulinum toxin for medical use for use in the treatment of glabellar linesmuscular rigidityblepharospasmcervical dystoniahyperhidrosisstrabismusprostate disordermigraine headacheurge incontinenceurinary retention that is secondary to a hypertrophied bladder neckrecalcitrant voiding dysfunctionurge incontinenceneurogenic bladder dysfunction and pelvic pain; Pharmaceutical preparationsacne medicationsacne treatment preparationsadrenal hormone preparationsalcohol for topical useallergy and allergy relief medicationsanalgesicsandrogen preparationsanesthetics for surgical and non-surgical useantacidsbactericidesantiarrhythmicsantibioticsanticoagulantsanticonvulsantsantidepressantsantidiabetic preparationsantiviralsanti-cancer preparationsanti-infectivesanti-inflammatoriesantipyreticsantibacterial pharmaceuticalscalcium channel blockersbeta blockerschemical compounds for drug deliveryeye dropseye patches for medical purposeshair growth stimulantsvaccinesvaccine adjuvantsvaccine stabilizersdiureticsamino acids for medical purposes; Medicines for the treatment of gastrointestinal diseases; chemical preparations for pharmaceutical purposes for the treatment of glabellar linesmuscular rigidityblepharospasmcervical dystoniahyperhidrosisstrabismusprostate disordermigraine headacheurge incontinenceurinary retention that is secondary to a hypertrophied bladder neckrecalcitrant voiding dysfunctionurge incontinenceneurogenic bladder dysfunctionpelvic pain; chemico-pharmaceutical preparations for the treatment of glabellar linesmuscular rigidityblepharospasmcervical dystoniahyperhidrosisstrabismusprostate disordermigraine headacheurge incontinenceurinary retention that is secondary to a hypertrophied bladder neckrecalcitrant voiding dysfunctionurge incontinenceneurogenic bladder dysfunctionpelvic pain; drugs for medical purposes for the treatment of glabellar linesmuscular rigidityblepharospasmcervical dystoniahyperhidrosisstrabismusprostate disordermigraine headacheurge incontinenceurinary retention that is secondary to a hypertrophied bladder neckrecalcitrant voiding dysfunctionurge incontinenceneurogenic bladder dysfunctionpelvic pain; Medicines for human purposes for the treatment of glabellar linesmuscular rigidityblepharospasmcervical dystoniahyperhidrosisstrabismusprostate disordermigraine headacheurge incontinenceurinary retention that is secondary to a hypertrophied bladder neckrecalcitrant voiding dysfunctionurge incontinenceneurogenic bladder dysfunctionpelvic pain; pharmaceutical preparations for activating cellular function; Adjuvants for medical purposes; pharmaceutical preparations for central nerve treatmentfor the treatment of sequelae caused by damage to the central nerve in the brain; dermatological pharmaceutical productsinjectable botulinum toxin for refining wrinkles; pharmaceutical preparations for treating skin disorders; antibiotic preparations; pharmaceutical preparations for chemical disorder treatmentfor treatment of chemical imbalance in the brain
Publications
History of USPTO decisions and trademark events.
8 publications found
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/15/2022
PUBO
PUBLISHED FOR OPPOSITION
02/15/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/26/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/12/2022
DOCK
ASSIGNED TO EXAMINER
01/12/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/09/2021
NWAP
NEW APPLICATION ENTERED
05/11/2021
Continuous trademark protection
Get notified about every new filing that threatens CLODEW or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.